Attachment
Gates Package, p.255 · gates:exh:00148
Page text: p.255 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership
Carlos Garner, Ph.D.
Vice President, Global Regulatory Affairs
Eli Lilly and Company
David Goff, M.D., Ph.D.
Director, Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute, NIH
Penny Heaton, Ph.D.
Chief Executive Officer
Bill & Melinda Gates Medical Research Institute
Michael Kurilla, M.D., Ph.D. (Co-Chair)
Director, Division of Clinical Innovation
National Center for Advancing Translational Sciences, NIH
George Mensah, M.D.
Director, Center for Translation Research & Implementation Science
National Heart, Lung, and Blood Institute, NIH
Seema Nayak, M.D.
Director, Office of Clinical Research Resources
National Institute of Allergy and Infectious Diseases, NIH
Manizhe Payton, M.P.H.
Director, Office of Clinical Site Oversight, DAIDS
National Institute of Allergy and Infectious Diseases, NIH
Laura Resnansky, B.S.N.
Vice President, Global Head of Clinical Operations - Immunology, Infectious Diseases, Ophthalmology
and Neuroscience
Genentech
Christine Sizemore, Ph.D.
Director, Division of International Relations
Fogarty International Center, NIH
Badhri Srinivasan, A.B.D., M.S.
Head, Global Development Operations
Novartis
Peter Stein, M.D.
Director of Office of New Drugs, Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Therese Takas
Director, Clinical Operations
AstraZeneca